Announce your event here
POC and mHealth Diagnostics Summit
2014-11-05 to 2014-11-07
Boston, MA, USA
The growth and proliferation of point-of-care testing and mobile health devices is an indicator of the transformation in the IVD market, driven by the need to reduce the cost of healthcare and shorten the time required to get test results. A newly emerging DTC segment will meet the needs of consumers who are willing to pay out of pocket to manage their own health information by creating an array of tools designed to enable preventative medicine. This inaugural event will highlight advances in the rapid testing market in two sections: the development of technologies and the progression to the clinical and consumer interface.

http://www.healthtech.com/poc-mhealth-diagnostics-summit/external link

Advances in Prenatal Molecular Diagnostics
2014-11-05 to 2014-11-07
Boston, MA, USA

The field of prenatal diagnostics is undergoing rapid and significant change, as a variety of molecular diagnostics are transforming the type and quality of data that can be provided to pregnant women and their physicians. Array-based cytogenetic analysis can provide more detailed and accurate assessment of many genetic conditions compared with traditional karyotyping, both of which rely on samples obtained using invasive procedures. Since obtaining samples invasively, even in the most proficient hands, does involve some risk to the fetus, there has been tremendous interest in non-invasive testing approaches. Next-gen sequencing of cell-free DNA found in maternal blood has been demonstrated to provide highly accurate assessment of fetal aneuploidies, with quite low false positives and false negatives, in most cases. Best practice guidelines have been modified quite quickly to recommend that such testing be offered to women who are at increased risk of aneuploidies, either because of past history, advanced maternal age or other reasons, and adoption and agreement by insurers to cover such testing has occurred at unprecedented speed. Such tests are not without controversy, however, because they only test for the most common chromosome duplications, and are unable thus far to provide analysis of smaller genetic insertions, deletions and rearrangements. One alternative approach has been research on obtaining circulating fetal cells from maternal blood, which would offer the advantages of being non-invasive, and isolated from confounding maternal DNA, but the challenges of reliably obtaining such rare cells has delayed the prospects for commercialization. This conference will provide an in-depth examination of key issues, technical and practical developments in these areas, and opportunities for discussing some of the issues that will have an impact on how this field continues to quickly evolve in the near future.

http://www.healthtech.com/prenatal-diagnosticsexternal link